Autosomal Recessive Severe Congenital Neutropenia due to Glucose-6-Phosphatase Catalytic Subunit 3 (G6PC3) Deficiency

Autosomal recessive severe congenital neutropenia due to glucose-6-phosphatase catalytic subunit 3 (G6PC3) deficiency is a rare, inherited condition. A baby is born with very low numbers of a specific white blood cell called a neutrophil. Neutrophils fight bacteria and help wounds heal. When neutrophils are very low, the body cannot stop infections well. Doctors call this severe congenital neutropenia (SCN). In G6PC3 deficiency, the gene named G6PC3 does not work the way it should. The child must get the faulty gene from both parents (autosomal recessive). Some children have only the low neutrophils. Other children also have heart or kidney/urinary tract differences, and the skin may show large, visible surface veins. The condition may be called SCN type 4 (SCN4). The problem begins before birth and continues through life. Without treatment, infections can be frequent and serious. With treatment, many children do better and can live active lives. NCBI+2PMC+2

The G6PC3 enzyme sits in a cell compartment and helps manage glucose handling. When it is defective, neutrophil precursors in the bone marrow face energy stress and ER stress. This stress triggers early cell death and maturation arrest, so few mature cells enter the blood. The neutrophils that do circulate may move less well (poor chemotaxis), express lower levels of adhesion molecules (like CD11b), and may produce less reactive oxygen needed to kill bacteria (weaker oxidative burst). Together, these changes cause frequent infections and slow healing. The same genetic problem can affect other tissues during development, explaining the visible veins and some heart or urogenital differences in the “classic” form. New England Journal of Medicine+3PubMed+3ashpublications.org+3

G6PC3 deficiency is a rare, inherited (autosomal recessive) immune disorder where the body makes too few neutrophils (a type of white blood cell), starting at birth. Children and adults have repeated bacterial infections and mouth, skin, lung, or liver infections. Many have extra features such as visible superficial veins and heart or urinary tract differences. The mainstay of care is granulocyte colony-stimulating factor (G-CSF) to raise neutrophils, prompt antibiotics for fever, and, in selected cases, stem-cell transplant. NCBI+2orpha.net+2

The G6PC3 gene helps neutrophils manage energy inside the cell. Harmful variants stress the endoplasmic reticulum and make neutrophils die too early or move and kill germs poorly. This causes lifelong low counts and frequent infections unless supported with treatment. New England Journal of Medicine+1

Other names

You may see different names in reports, articles, or clinic notes:

• G6PC3 deficiency

• Severe congenital neutropenia type 4 (SCN4)

• Autosomal recessive severe congenital neutropenia due to G6PC3

• Dursun syndrome (a term used in some reports for the “classic” form with heart and urogenital findings)

• Syndromic severe congenital neutropenia due to G6PC3

• Congenital neutropenia-4
  All these labels refer to the same genetic cause: harmful (pathogenic) changes in the G6PC3 gene. NCBI+1

Types

Doctors talk about a “phenotypic spectrum.” That means one gene change can show up in different ways. For G6PC3 deficiency, two main patterns are described:

1. Isolated (non-syndromic) severe congenital neutropenia.
   The child has very low neutrophils and frequent infections but no consistent heart or kidney/urinary tract differences. ScienceDirect

2. Classic (syndromic) G6PC3 deficiency.
   The child has severe neutropenia plus other findings such as visible, prominent superficial veins, heart structure differences, and/or urogenital differences (for example, undescended testes in boys or kidney/urinary tract changes). NCBI+2New England Journal of Medicine+2

Causes

In this section “cause” means what drives neutropenia and symptoms in G6PC3 deficiency. Each paragraph is short and simple.

1. Harmful changes in the G6PC3 gene.
   Mistakes in the DNA code (missense, nonsense, frameshift, splice) stop the G6PC3 protein from working well. New England Journal of Medicine

2. Autosomal recessive inheritance.
   A child inherits one faulty copy from each parent. Parents are usually healthy carriers. NCBI

3. Low glucose-6-phosphatase activity in immune cells.
   The G6PC3 enzyme helps control cell energy and sugar handling. When it is weak, neutrophils cannot function or mature well. PMC

4. Endoplasmic reticulum (ER) stress.
   The cell’s protein-folding “factory” is stressed, which harms developing neutrophils. PubMed

5. Increased cell death of neutrophil precursors.
   Young neutrophils in bone marrow die earlier than they should, so few reach the blood. PMC

6. Maturation arrest in the bone marrow.
   Neutrophil development stops midway, often at the promyelocyte/myelocyte stage. BioMed Central

7. Defective oxidative burst.
   Neutrophils make less reactive oxygen needed to kill bacteria. Frontiers

8. Poor chemotaxis (cell movement).
   Neutrophils do not move well toward infection signals, so they arrive late. Frontiers

9. Reduced surface adhesion proteins (e.g., CD11b expression).
   This makes it harder for neutrophils to stick to blood vessel walls and enter tissues. ashpublications.org

10. Possible glycosylation defects.
    Abnormal sugar chains on proteins can disturb neutrophil function. ResearchGate

11. Body-wide effects on small vessels and connective tissue.
    This can show as visible superficial veins in the skin. PMC

12. Associated heart differences.
    Structural heart differences can occur as part of the same genetic condition (the “classic” syndromic form). New England Journal of Medicine

13. Associated urogenital differences.
    Kidney/urinary tract differences or undescended testes may appear in some children. NCBI

14. Consanguinity (parents related by blood) increases risk.
    It raises the chance both parents carry the same rare variant. (Epidemiology in case series suggests this in some families.) BioMed Central

15. Founder variants in some regions.
    Some families share the same mutation due to a common ancestor. (Reported in cohorts.) BioMed Central

16. Compound heterozygosity.
    A child can inherit two different harmful variants, one from each parent. NCBI

17. Intercurrent infections can unmask severity.
    Even minor infections can become serious because neutrophils are too few or weak. BioMed Central

18. Mouth flora imbalance.
    Low neutrophils allow mouth bacteria to overgrow, causing gum disease. BioMed Central

19. Skin barrier challenges.
    Small skin breaks can become large infections because of poor early neutrophil response. BioMed Central

20. Delayed or inadequate treatment.
    Without timely use of antibiotics or granulocyte colony-stimulating factor (G-CSF), infection risk rises. (General SCN care principle.) BioMed Central

Common symptoms and signs

1. Frequent bacterial infections.
   Ear infections, sinus infections, pneumonia, and skin infections happen often because neutrophils are low. BioMed Central

2. Fevers that come with minor illnesses.
   Because defenses are weak, even small infections cause high fevers. BioMed Central

3. Skin abscesses and boils.
   Pus-filled pockets form easily and may recur. BioMed Central

4. Mouth ulcers.
   Painful sores inside the mouth occur often and heal slowly. BioMed Central

5. Gingivitis and periodontitis.
   Gums bleed, swell, and pull away from teeth; tooth loss can occur if untreated. BioMed Central

6. Visible, prominent superficial veins.
   Thin, branching veins on the chest or limbs may be obvious. PMC

7. Poor wound healing.
   Cuts or surgical wounds take longer to heal and can get infected. BioMed Central

8. Sepsis (bloodstream infection).
   This is a medical emergency and can be life-threatening. BioMed Central

9. Pneumonia.
   Cough, fast breathing, chest pain, and fever may occur, often more than once. BioMed Central

10. Ear and sinus infections.
    These can be stubborn and recur despite treatment. BioMed Central

11. Bone marrow problems.
    Doctors may note “maturation arrest” on bone marrow tests. Children do not feel this, but it explains the low neutrophils. BioMed Central

12. Heart differences (subset).
    Some children have structural heart issues found on echocardiogram. New England Journal of Medicine

13. Urogenital differences (subset).
    Some have kidney/urinary tract changes or undescended testes. NCBI

14. Large platelets (rarely reported).
    A few cases showed unusually large platelets on blood smear. BioMed Central

15. General tiredness during infections.
    Low energy and poor appetite may come with repeated infections. (General SCN presentation.) BioMed Central

Diagnostic tests

A. Physical examination (at the bedside)

1. Vital signs and fever check.
   Checking temperature, heart rate, and breathing helps judge infection severity fast. Fever with neutropenia is an emergency. BioMed Central

2. Skin and soft tissue inspection.
   Doctors look for cellulitis, abscesses, and wound problems. Early signs guide urgent antibiotics. BioMed Central

3. Oral and dental exam.
   Ulcers, gum swelling, and loose teeth suggest chronic neutropenia. Dental care is part of management. BioMed Central

4. Lymph node and spleen check.
   Tender nodes or enlarged spleen can signal active or repeated infections. BioMed Central

5. Look for prominent superficial veins and congenital clues.
   Visible veins, heart murmurs, or genital/kidney anomalies point toward the “classic” syndromic form. PMC+1

B. Bedside / manual clinical maneuvers

6. Focused respiratory exam (listening to lungs).
   Crackles or wheeze may suggest pneumonia and guide imaging. BioMed Central

7. Focused ENT exam (ears, nose, throat).
   Ear fluid, sinus tenderness, or throat redness point to bacterial infection needing prompt care. BioMed Central

8. Wound probing and drainage assessment.
   Gentle bedside assessment of abscesses helps decide if drainage is needed. BioMed Central

9. Gingival probing by dentistry.
   Simple manual gum assessment identifies periodontitis severity. BioMed Central

10. Abdominal palpation.
    Tenderness can suggest deep infections (e.g., intra-abdominal). It directs imaging or cultures. BioMed Central

C. Laboratory and pathological tests

11. Complete blood count (CBC) with differential and absolute neutrophil count (ANC).
    ANC is usually very low (<0.5 ×10⁹/L). This confirms neutropenia. BioMed Central

12. Blood culture during fever.
    This finds the bacteria in the bloodstream and guides antibiotic choice. BioMed Central

13. Inflammation markers (CRP/ESR).
    These help track infection severity and response to treatment. BioMed Central

14. Peripheral blood smear.
    A smear can show neutropenia and other clues (occasionally large platelets have been reported). BioMed Central

15. Bone marrow aspiration/biopsy.
    Often shows maturation arrest of neutrophil precursors; rules out other causes. BioMed Central

16. Neutrophil functional assays (e.g., oxidative burst by DHR flow cytometry, chemotaxis).
    These can show defects in killing and movement. Frontiers

17. Targeted genetic testing for G6PC3 variants.
    Single-gene sequencing, multigene SCN panels, or exome sequencing confirm the diagnosis. Sanger can validate results; copy-number testing can look for deletions/duplications. orpha.net+1

D. Electrodiagnostic / physiology-based tests

18. Electrocardiogram (ECG).
    Screens heart rhythm and may support evaluation of structural heart disease in the syndromic form. New England Journal of Medicine

E. Imaging tests

19. Echocardiogram.
    Looks for congenital heart differences seen in the classic form. New England Journal of Medicine

20. Renal and bladder ultrasound; chest X-ray or chest CT when needed.
    Ultrasound checks kidney/urinary tract anatomy. Chest imaging checks for pneumonia or abscess. NCBI+1

Non-pharmacological treatments (therapies & other supports)

1. Personal hand hygiene program.
   Description (≈100 words): Wash hands with soap and water for 20 seconds before eating, after bathroom use, and after public surfaces; use alcohol hand rub when soap/water are not available. Remind caregivers to do the same. Carry a pocket sanitizer. Keep nails short and avoid biting.
   Purpose: Reduce everyday germ exposure that can trigger severe infections when neutrophils are low.
   Mechanism: Mechanical removal and alcohol-based inactivation of pathogens on hands lowers transmission to mouth, nose, and broken skin. CDC+1

2. Food safety “clean–separate–cook–chill.”
   Description: Follow safe shopping, storage, and cooking rules; use a thermometer; avoid cross-contamination; refrigerate quickly.
   Purpose: Prevent food-borne infection.
   Mechanism: Heat kills microbes; separation and chilling slow growth and reduce inoculum size. U.S. Food and Drug Administration+1

3. Avoid high-risk foods when counts are very low.
   Description: Skip raw/undercooked meats, fish/sushi, runny eggs; unwashed produce; raw sprouts; unpasteurized milk, juice, or soft cheeses; reheat deli meats until steaming.
   Purpose: Lower exposure to Listeria, Salmonella, E. coli, and other pathogens.
   Mechanism: High-risk foods carry higher bacterial loads; cooking/pasteurization inactivates pathogens. CDC+1

4. Prompt “fever plan”.
   Description: Treat any fever ≥38.0°C (100.4°F) as an emergency: go to the hospital now for blood cultures and empiric antibiotics within 1 hour. Keep a written plan.
   Purpose: Early treatment prevents sepsis.
   Mechanism: Rapid broad-spectrum antibiotics cover likely pathogens while counts are low. Infectious Diseases Society of America+1

5. Oral and dental care routine.
   Description: Twice-daily brushing with fluoride toothpaste, daily flossing if platelets allow, and short-term chlorhexidine mouthwash during mouth ulcers or gingivitis as advised. Regular dentist visits.
   Purpose: Reduce gum infections and mouth ulcers, a common infection entry.
   Mechanism: Plaque control and antiseptics lower oral bacterial load. PMC+1

6. Skin care & wound rules.
   Description: Moisturize dry skin, treat cuts/scratches quickly (wash, antiseptic, clean bandage); avoid picking skin; prefer electric razors.
   Purpose: Prevent skin breaches from becoming deep infections or abscesses.
   Mechanism: Intact skin barrier plus rapid local antisepsis lowers bacterial entry. Merck Manuals

7. Environmental hygiene at home.
   Description: Routine cleaning of high-touch surfaces, careful laundry for soiled items, pet hygiene (litter boxes, scratches).
   Purpose: Reduce everyday exposure to pathogens.
   Mechanism: Fewer viable microbes on surfaces reduces transfer to hands/mucosa. CDC

8. Vaccination (inactivated vaccines on time).
   Description: Keep routine inactivated vaccines up to date (including influenza and pneumococcal). Discuss extra pneumococcal doses if advised.
   Purpose: Prevent vaccine-preventable infections that can become severe.
   Mechanism: Vaccination primes adaptive immunity even when neutrophils are low. CDC+1

9. Live-vaccine precautions.
   Description: Live bacterial vaccines (e.g., BCG, oral typhoid) are generally avoided with severe neutropenia; live viral vaccines may be allowed case-by-case—coordinate with immunology/hematology.
   Purpose: Avoid vaccine-derived infection risk where host defenses are reduced.
   Mechanism: Live organisms in vaccines can replicate; risk–benefit depends on immune status. PMC+1

10. School/work infection control.
    Description: Encourage sick contacts to stay away; use masks during outbreaks; ensure ready access to sinks/sanitizers.
    Purpose: Limit exposure during respiratory viral seasons that can lead to bacterial superinfection.
    Mechanism: Source control and hand hygiene interrupt droplet and contact spread. CDC

11. Seasonal & travel planning.
    Description: Pre-travel vaccines (inactivated), travel antibiotics plan, bottled/boiled water in high-risk settings, and medical letter about G-CSF and fever plan.
    Purpose: Prevent travel-related infections and delays in urgent care.
    Mechanism: Risk reduction and early therapy in environments with different pathogens. CDC

12. Household education & caregiver training.
    Description: Teach family to recognize fever, mouth sores, cellulitis, and to seek care fast; review the hand/food rules.
    Purpose: Early detection and action save lives in neutropenia.
    Mechanism: Shortening “symptom-to-antibiotic” time reduces progression to sepsis. PubMed

13. Dental/sinus surgical source control when needed.
    Description: Drain abscesses; address chronic sinus disease surgically if medical therapy fails.
    Purpose: Remove persistent infection foci that relapse while neutropenic.
    Mechanism: Source control plus antibiotics clear deep infections. Medscape

14. Central line best practices (if used).
    Description: Use lines only when necessary; follow sterile access protocols; consider antiseptic caps.
    Purpose: Prevent catheter-related bloodstream infection.
    Mechanism: Barrier precautions and antisepsis lower line colonization. CDC

15. Sun/skin protection & minor injury prevention.
    Description: Closed-toe shoes, gloves for chores, insect repellents, and sunscreen to avoid bites/scrapes that can get infected.
    Purpose: Reduce portals of entry for bacteria.
    Mechanism: Physical barriers prevent breaks in skin. Merck Manuals

16. Psychosocial support & adherence coaching.
    Description: Routine counseling for chronic disease stress; reminders for daily hygiene, G-CSF schedules, and clinic visits.
    Purpose: Better adherence reduces infection episodes.
    Mechanism: Behavioral support improves consistent risk-reduction behaviors. PMC

17. Bone health measures.
    Description: Weight-bearing activity as tolerated and vitamin D/calcium intake per local guidance (with clinician advice).
    Purpose: SCN can be associated with low bone density; keeping bones strong lowers fracture risk.
    Mechanism: Exercise and adequate micronutrients support bone remodeling. MedlinePlus

18. Outbreak precautions (household & clinic).
    Description: During flu/RSV surges, consider mask use indoors, avoid crowded poorly ventilated spaces, and prioritize updated vaccines.
    Purpose: Lower viral infections that can complicate neutropenia.
    Mechanism: Masks and distancing reduce droplet spread. CDC

19. Written emergency card/plan.
    Description: Carry a wallet card: “Severe congenital neutropenia (G6PC3). Fever ≥38.0°C is an emergency. Needs prompt cultures and empiric IV antibiotics.”
    Purpose: Speed correct triage in unfamiliar hospitals.
    Mechanism: Reduces delays to first antibiotic dose. PubMed

20. Specialist follow-up (registry/guidelines).
    Description: Regular hematology/immunology visits; consider enrollment in SCN registries that follow counts, infections, and leukemia risk.
    Purpose: Optimize G-CSF dosing, monitor complications, plan HSCT if needed.
    Mechanism: Guideline-based care improves outcomes; registries guide dosing and risk. PMC+2PMC+2

---

Drug treatments

Important: Drug choice, dose, and timing must be individualized by your clinician. Below are commonly used and/or guideline-supported drugs in SCN care. G-CSF agents are core disease-directed therapy; anti-infectives treat or prevent infections in high-risk neutropenia. FDA labeling is cited for each medicine’s indications/dosing/safety; some uses in congenital neutropenia (e.g., prophylaxis regimens) follow IDSA/ASCO guidance rather than the label.

Core disease-directed (neutrophil growth factors)

1. Filgrastim (NEUPOGEN®) — recombinant G-CSF.
   Class: Hematopoietic growth factor. Dose/Time: Titrated subcutaneously (e.g., 5–10 mcg/kg/day and individualized). Purpose: Raise ANC, reduce infections, mouth ulcers, and hospitalizations in severe chronic neutropenia (SCN). Mechanism: Stimulates bone-marrow neutrophil production and release. Side effects: Bone pain, splenomegaly, rare serious events (e.g., glomerulonephritis, ARDS). Evidence: FDA label includes use in severe chronic neutropenia (congenital, cyclic, idiopathic). FDA Access Data

2. Pegfilgrastim (NEULASTA® and biosimilars).
   Class: Long-acting G-CSF. Dose/Time: Typically 6 mg SC per chemotherapy cycle in oncology; in SCN some experts use off-label schedules when daily filgrastim is impractical—specialist decision. Purpose/Mechanism: Same as filgrastim with longer half-life for fewer injections. Side effects: Bone pain; rare splenic rupture, ARDS, capillary leak. Evidence: FDA label covers chemotherapy-induced neutropenia; safety profile and G-CSF mechanism apply. Use in SCN is specialist-guided. FDA Access Data

3. Tbo-filgrastim (GRANIX®).
   Class: G-CSF. Use: Similar to filgrastim; oncology-approved; sometimes used when access or tolerance issues arise—specialist decision. Mechanism/SE: As above. Evidence: FDA labeling supports neutrophil recovery in chemotherapy; congenital neutropenia use is by expert practice. FDA Access Data

4. Filgrastim-sndz (ZARXIO®) / other filgrastim biosimilars.
   Class/Use: Biosimilar filgrastim used per filgrastim principles when appropriate. Mechanism/SE: As above. Evidence: FDA-approved biosimilar status with same mechanism and safety class. FDA Access Data

5. Sargramostim (LEUKINE®; GM-CSF).
   Class: GM-CSF. Use: Selected cases with inadequate G-CSF response (specialist guided). Mechanism: Stimulates myeloid precursors (broader than G-CSF). SE: Fever, bone pain, capillary leak. Evidence: FDA label for myeloid reconstitution (not specific to SCN). FDA Access Data

Empiric therapy for febrile neutropenia / severe infections

6. Cefepime (4th-gen cephalosporin).
   Purpose: First-line monotherapy for high-risk febrile neutropenia in many protocols; strong gram-negative including Pseudomonas coverage. Dose/Time: IV every 8–12 h as per label/renal function. Mechanism: Inhibits bacterial cell wall synthesis. SE: Neurotoxicity risk with renal failure. FDA Access Data

7. Piperacillin–tazobactam.
   Purpose: Broad anti-pseudomonal coverage; alternative empiric monotherapy. Mechanism: Beta-lactam with beta-lactamase inhibitor; blocks cell wall synthesis. SE: Electrolyte load, hypersensitivity. FDA Access Data

8. Meropenem.
   Purpose: Broad carbapenem option when resistant organisms suspected. Mechanism: Beta-lactam that resists many beta-lactamases. SE: Seizure risk (rare). FDA Access Data

9. Vancomycin.
   Purpose: Add if MRSA risk, catheter infection signs, or hemodynamic instability. Mechanism: Inhibits gram-positive cell wall synthesis. SE: Nephrotoxicity, “red man” reaction. FDA Access Data

10. Levofloxacin (oral/IV).
    Purpose: Prophylaxis in selected high-risk prolonged neutropenia (per ASCO/IDSA) or step-down therapy; avoid if already on FQ prophylaxis. Mechanism: DNA gyrase/topoisomerase inhibitor. SE: Tendon, CNS/QT effects. Infectious Diseases Society of America+1

11. Ciprofloxacin.
    Purpose: Alternative fluoroquinolone in certain prophylaxis/step-down settings (guideline-directed). Mechanism/SE: As class. FDA Access Data

12. Posaconazole.
    Purpose: Antifungal prophylaxis for profound, prolonged neutropenia at high mold risk; sometimes used in SCN during HSCT or severe courses. Mechanism: Triazole blocking ergosterol synthesis. SE: Hepatic/QT interactions. Infectious Diseases Society of America+1

13. Voriconazole.
    Purpose: Treatment of invasive aspergillosis; used when mold infection suspected. Mechanism: Triazole; inhibits ergosterol synthesis. SE: Visual changes, hepatic effects, drug interactions. FDA Access Data

14. Fluconazole.
    Purpose: Yeast coverage (Candida) for treatment/prophylaxis in selected settings. Mechanism: Triazole; ergosterol pathway inhibition. SE: Hepatic/QT interactions. FDA Access Data

15. Amphotericin B (lipid complex).
    Purpose: Broad fungicidal therapy for severe fungal infections. Mechanism: Binds ergosterol, forms pores. SE: Infusion reactions, nephrotoxicity (less with lipid forms). FDA Access Data

16. Acyclovir.
    Purpose: HSV prophylaxis/treatment in seropositive patients during profound neutropenia/HSCT per ASCO/IDSA. Mechanism: Viral DNA polymerase inhibitor. SE: Renal crystal risk; hydrate. PubMed+1

17. TMP-SMX (co-trimoxazole).
    Purpose: Pneumocystis prophylaxis when indicated (e.g., post-HSCT or with immunosuppressants). Mechanism: Folate pathway blockade. SE: Cytopenias, allergy. PubMed

18. Amoxicillin/clavulanate (oral outpatient regimens).
    Purpose: With a fluoroquinolone for selected low-risk febrile neutropenia managed as outpatient per ASCO/IDSA. Mechanism: Beta-lactam + inhibitor; broad gram-positive/negative coverage. SE: GI upset. PubMed

19. Empagliflozin (special situations, emerging evidence).
    Purpose: Experimental/adjunct in case reports of G6PC3 neutropenia improving neutrophil function; not standard—only in research/specialist settings. Mechanism: SGLT2 inhibition may alter neutrophil metabolism/ER stress; evidence limited to reports. SE: Genitourinary infections, ketoacidosis risk. PMC

20. Growth-factor support around surgery/infections (strategy).
    Purpose: Temporary G-CSF dose adjustments during infections/procedures to maintain ANC targets (specialist-directed). Mechanism: Short-term ANC boosting lowers immediate infectious risk. Evidence: SCN registry experience and guidelines. PMC+1

---

Dietary molecular supplements

1. Vitamin D.
   What it does (≈70–100 words): Supports innate and adaptive immunity and may modulate antimicrobial peptides. Correct deficiency per local lab ranges. Dose: Per clinician (often 600–2000 IU/day to maintain sufficiency; higher if deficient). Function/Mechanism: Nuclear receptor signaling influences immune gene expression. Note: Do not megadose. FDA Access Data

2. Zinc.
   Use: Essential for neutrophil function and wound healing; supplement only if low. Dose: Typically 8–11 mg/day dietary total; short-term supplements guided by labs. Mechanism: Cofactor for many enzymes and immune signaling; deficiency impairs chemotaxis. Caution: Excess zinc can cause copper deficiency. FDA Access Data

3. Vitamin C.
   Use: Antioxidant supporting barrier function; correct dietary insufficiency. Dose: RDA 75–90 mg/day; higher short-term doses only with clinician. Mechanism: Redox balance may support neutrophil function and oxidative burst. FDA Access Data

4. Omega-3 fatty acids.
   Use: Anti-inflammatory lipid mediators; dietary sources preferred (fish). Mechanism: Competes with arachidonic acid pathways; effects on infection risk are mixed. Caution: Bleeding risk at high doses. FDA Access Data

5. Probiotics (with caution).
   Use: Gut microbiome support; avoid in profound neutropenia or central lines unless your team approves. Mechanism: Competes with pathogens and modulates immunity; rare cases of bacteremia/fungemia reported. OUP Academic

6. Protein-adequate nutrition.
   Use: Sufficient calories and protein for healing and immune cell production; involve a dietitian. Mechanism: Supplies amino acids for leukocyte proteins. Evidence: General immune nutrition principles for immunocompromised hosts. U.S. Food and Drug Administration

7. Folate & B12 (if deficient).
   Use: Correct verified deficiencies that impair blood-cell production. Mechanism: DNA synthesis in marrow precursors. Merck Manuals

8. Iron (if deficient).
   Use: Treat iron-deficiency anemia under supervision; avoid unnecessary iron during active infection. Mechanism: Hemoglobin and cellular enzymes. Merck Manuals

9. Selenium (dietary sufficiency).
   Use: Antioxidant enzyme cofactor; avoid high-dose supplements. Mechanism: Glutathione peroxidase activity supports redox balance. FDA Access Data

10. Multivitamin at RDA levels.
    Use: Fills small dietary gaps without megadoses. Mechanism: Provides baseline micronutrients for immune pathways. U.S. Food and Drug Administration

---

Immunity-booster / regenerative / stem-cell–related drugs

1. Filgrastim (G-CSF).
   Raises neutrophils by stimulating marrow; cornerstone of SCN care; dosing individualized; main risks include bone pain and rare serious events. FDA Access Data

2. Pegfilgrastim (long-acting G-CSF).
   Long half-life alternative when appropriate; specialist determines fit for congenital cases. FDA Access Data

3. Sargramostim (GM-CSF).
   Broader myeloid stimulation when G-CSF response is inadequate or specific indications exist. FDA Access Data

4. Plerixafor (MOZOBIL®).
   CXCR4 antagonist used to mobilize hematopoietic stem cells for collection before HSCT; not a routine SCN daily therapy but part of regenerative strategies. FDA Access Data

5. IV Immunoglobulin (IVIG).
   In selected patients with coexisting antibody defects or recurrent specific infections, IVIG may be used; not standard for all SCN. CDC

6. Peri-transplant conditioning agents (context).
   Busulfan, fludarabine, ATG are used around allogeneic HSCT, the only curative option for non-responders or those with malignant evolution; drug choices and doses are transplant-team specific. Frontiers

---

Surgeries / procedures

1. Allogeneic hematopoietic stem-cell transplantation (HSCT).
   Procedure: Infuse donor stem cells after conditioning to replace the marrow. Why: Curative option for SCN patients who fail G-CSF or transform to MDS/AML. ashpublications.org+1

2. Central venous access placement (when needed).
   Procedure: Surgical insertion of a port or tunneled catheter. Why: Reliable access for IV antibiotics, transfusions, or parenteral therapy in complex courses. CDC

3. Incision and drainage of abscess.
   Procedure: Open and drain pus collections; send cultures; continue antibiotics. Why: Source control when deep or refractory infections occur. PMC

4. Functional endoscopic sinus surgery (selected cases).
   Procedure: Endoscopic opening of blocked sinuses. Why: Repeated bacterial sinusitis despite maximal medical therapy. Medscape

5. Dental/periodontal procedures.
   Procedure: Drain dental abscess, debride, or extract non-salvageable teeth with prophylactic antibiotics per dentist/hematology plan. Why: Remove chronic oral infection sources. PMC

---

Preventions

1. Hand hygiene every time you return home, before eating, and after bathroom use. CDC

2. Follow the food safety four: clean, separate, cook, chill. U.S. Food and Drug Administration

3. Avoid high-risk foods during low counts; choose pasteurized and well-cooked options. CDC

4. Keep up-to-date with inactivated vaccines; ask about flu and pneumococcal vaccines. CDC

5. Make a written fever plan and act on fever immediately. PubMed

6. Daily oral care; see a dentist regularly. Mayo Clinic

7. Protect skin; treat cuts fast; avoid picking. Merck Manuals

8. Avoid sick contacts; use masks during outbreaks. CDC

9. Keep clinic and lab appointments to adjust G-CSF safely and monitor counts. PMC

10. Seek specialist care and consider registry enrollment for best-practice monitoring. SCNIR Site

---

When to see doctors

Go to the emergency department now for: any fever ≥38.0°C, shaking chills, shortness of breath, chest pain, confusion, rapidly spreading skin redness, severe mouth ulcers preventing fluids, or signs of sepsis (fast heart rate, low blood pressure). Neutropenic fever needs blood cultures and empiric IV antibiotics within 1 hour. Infectious Diseases Society of America+1

Call your team within 24 hours for: new mouth sores, skin pustules/boils, painful urination, persistent cough, sinus pain, or G-CSF side effects (severe left-upper-abdominal pain—possible spleen issue). FDA Access Data

---

What to eat & what to avoid

1. Eat: Well-cooked poultry/meat to FDA temperatures; Avoid: rare meats/undercooked burgers. U.S. Food and Drug Administration+1

2. Eat: Pasteurized milk/yogurt/cheese; Avoid: unpasteurized dairy and soft cheeses unless pasteurized. U.S. Food and Drug Administration

3. Eat: Thoroughly washed, peeled, or well-cooked fruits/veggies; Avoid: unwashed produce and all raw sprouts. CDC

4. Eat: Freshly prepared hot foods; Avoid: salad bars, deli cold cuts unless reheated steaming hot. CDC

5. Drink: Safe water (treated/boiled if unsure); Avoid: unfiltered well water/ice of unknown safety. MD Anderson Cancer Center

6. Eat: Fully cooked eggs; Avoid: runny yolks, homemade mayonnaise with raw egg. CDC

7. Eat: Properly stored leftovers (≤3–4 days); Avoid: foods past “use by” dates. U.S. Food and Drug Administration

8. Eat: Well-cooked seafood; Avoid: raw oysters, sushi/sashimi. CDC

9. Principle: “Clean–separate–cook–chill” at every meal. U.S. Food and Drug Administration

10. Ask a dietitian for individualized plans during HSCT or severe neutropenia. U.S. Food and Drug Administration

---

Frequently Asked Questions

1. Is G6PC3 neutropenia lifelong?
   Yes, it starts early in life and usually persists, but treatment helps people live much safer lives. NCBI

2. What is the main treatment?
   Daily or tailored G-CSF (filgrastim) to raise neutrophils and cut infections; dose is individualized. PMC

3. Can pegfilgrastim replace daily shots?
   Sometimes experts use long-acting G-CSF, but congenital use is individualized; daily filgrastim has the most registry experience. FDA Access Data+1

4. Will I always need antibiotics at home?
   Not routinely. You need urgent IV antibiotics for fever. Some people receive prophylaxis during very high-risk periods, following ASCO/IDSA guidance. Infectious Diseases Society of America

5. What ANC is the goal?
   Teams often target ANC ≥1.0×10⁹/L to prevent infections, adjusting G-CSF to the lowest effective dose. PMC

6. What about leukemia risk?
   SCN in general carries a risk of MDS/AML over time; risk varies by gene and dose requirements; monitoring is essential. PMC

7. When is HSCT considered?
   For poor G-CSF responders, those needing very high doses, or those evolving to MDS/AML; HSCT is the only curative option. ashpublications.org

8. Are live vaccines allowed?
   Inactivated vaccines are recommended. Live bacterial vaccines are avoided; live viral vaccines may be considered case-by-case with your specialist. PMC

9. Do I need a “neutropenic diet”?
   Strict “no fresh produce” diets show no clear benefit; focus on food safety (clean, separate, cook, chill) and avoid high-risk foods. flcancer.com+1

10. Can mouthwash help mouth sores?
    Short courses of chlorhexidine can reduce plaque/gingivitis; use under dental/medical guidance. PMC

11. What if I get bone pain from G-CSF?
    This is common and usually temporary; your team may adjust dose or timing and suggest simple pain strategies. Report severe left-upper-abdominal pain (spleen). FDA Access Data

12. Can adults be diagnosed later?
    Yes. Some people are recognized later after recurrent infections; genetic testing confirms the cause. PMC

13. Does G6PC3 affect organs besides blood?
    Possible heart/urogenital differences and visible veins occur in the “classic” form; your team screens for them. NCBI

14. Are new treatments coming?
    Case reports suggest metabolic modulators (e.g., empagliflozin) might help some G6PC3 cases, but this is experimental. PMC

15. Who should coordinate my care?
    A hematologist/immunologist experienced in congenital neutropenia, following modern European/SCN registry guidance. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.